Lannett Company, Inc.
9000 State Road
Philadelphia
Pennsylvania
19136
United States
Tel: 800-325-9994
Fax: 215-333-9004
Website: http://www.lannett.com/
Email: info@lannett.com
376 articles about Lannett Company, Inc.
-
Lannett Successfully Emerges From Chapter 11 in Significantly Stronger Financial Position as the Company Remains on Track Toward Commercialization of Highly Promising Pipeline
6/16/2023
Lannett Company, Inc. announced that it and certain of its subsidiaries have successfully emerged from their Chapter 11 cases following the confirmation of its Plan of Reorganization on June 8, 2023.
-
Lannett Company, Inc. Files Prepackaged Chapter 11 Cases to Significantly Strengthen Financial Position
5/3/2023
Lannett Company, Inc. announced that it and certain of its subsidiaries have commenced prepackaged Chapter 11 cases in the United States Bankruptcy Court for the District of Delaware to effectuate the transactions contemplated by the Restructuring Support Agreement announced on May 1, 2023.
-
Lannett Company, Inc. Enters Into Restructuring Support Agreement
5/1/2023
Lannett Company, Inc. (OTCMKTS: LCIN) (the "Company" or "Lannett") today announced that, together with certain of its subsidiaries (collectively with the Company, as applicable, the "Company Parties"), it has entered into a Restructuring Support Agreement (the "RSA") with holders of more than 80% of its 7.750% senior secured notes due 2026.
-
NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS
4/20/2023
Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE.
-
Lannett Shares Update - April 04, 2023
4/4/2023
Lannett Company, Inc. shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.
-
Lannett Reports Improved Fiscal 2023 Second Quarter Financial Results; Raises Full-Year Guidance
2/1/2023
Lannett Company, Inc. reported financial results for its fiscal 2023 second quarter ended December 31, 2022.
-
LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1
1/25/2023
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes.
-
LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT
1/25/2023
Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m. Eastern Time on February 6, 2023.
-
LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS
1/4/2023
Lannett Company, Inc. (NYSE: LCI) today provided an update on the clinical advancement and development of its biosimilar insulin aspart and biosimilar insulin glargine products.
-
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM
11/7/2022
Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin aspart development programs.
-
LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE
11/2/2022
Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2023 first quarter ended September 30, 2022.
-
Lannett to Report Fiscal 2023 First-Quarter Financial Results, Host Conference Call on Wednesday, November 2
10/26/2022
Lannett Company, Inc. announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, after the market closes.
-
Lannett Receives FDA Approval to Manufacture Numbrino® at Seymour Plant
10/21/2022
Lannett Company, Inc. announced that it has received approval from the US Food and Drug Administration to manufacture Numbrino®, the company's branded topical anesthetic product, at its main plant in Seymour, Indiana.
-
Lannett Announces Sale of Several Discontinued Generic Drugs
10/19/2022
Lannett Company, Inc. announced that it has recently sold previously discontinued abbreviated new drug applications for approximately $3 million to a privately held pharmaceutical company.
-
LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE
8/31/2022
Lannett Company, Inc. (NYSE: LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).
-
LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS
8/24/2022
Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 fourth quarter and full year ended June 30, 2022.
-
LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24
8/19/2022
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 fourth quarter and full year on Wednesday, August 24, 2022, after the market closes.
-
Societal CDMO Announces Signing of Amendment to License and Supply Agreement With Lannett for Marketing of Verapamil PM and Verelan SR Products
7/12/2022
Societal CDMO, Inc. announced that it has signed an amendment to its license and supply agreement with Lannett Company for the marketing of Verapamil PM and Verelan SR products.
-
LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE
6/1/2022
Lannett Company, Inc. (NYSE: LCI) today provided an update on its ongoing pivotal clinical trial of biosimilar insulin glargine.
-
Lannett Enters Agreement to Be Exclusive U.S. Distributor of Fludarabine Phospate for Injection, USP
5/12/2022
Lannett Company, Inc. announced that it has entered into an agreement with Areva Pharmaceuticals to be the exclusive U.S. distributor of Fludarabine Phosphate for injection, USP, 50 mg/2mL, single dose vials.